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Abstract
Background Common variable immunodeficiency disorders
(CVIDs) represents a heterogeneous disease spectrum that
includes recurrent infections and complications such as
autoimmunity, inflammatory organ disease and an increased
risk of cancer. A diagnostic delay is common in CVIDs
patients.
Purpose To determine the spectrum of clinical manifesta-
tions, immunological characteristics, and the time to diag-
nosis of 61 adult CVIDs and 18 patients with a partial
antibody deficiency (SADNI and IgG subclass deficiency).
Methods A retrospective cohort study was performed in
patients who met the ESID/PAGID for CVIDs, IgG subclass
deficiency and SADNI. Medical records were reviewed to
obtain patient demographics, clinical and laboratory data.
Results Infections were the main presentation of all anti-
body deficient patients and the number of patients with
infections declined during IgG therapy. The development
of bronchiectasis continued despite IgG therapy, as well as
the development of autoinflammatory conditions. Non-
infectious disease complications were present in 30% of
CVIDs patients at the time of diagnosis and this increased
to 51% during follow up despite IgG therapy. The most
common complications were autoimmunity or lymphopro-
liferative disease. The median time to diagnosis was 10 years
and in the patients with non-infectious complications the
time to diagnosis was considerably longer when compared
to the group of patients without complications (17.6 vs.
10.2 years, p00.026).
Conclusion In contrast to the partial antibody deficiencies
we found a considerable delay in the diagnosis of CVIDs,
especially in those patients who were dominated by non-
infectious complications, and thus increased awareness
would be beneficial. Pulmonary and other complications
may continue despite adequate IgG replacement therapy
suggesting other causes responsible for these complications.
Keywords Common variable immunodeficiency . clinical
manifestations . diagnostic delay . pulmonary disease .
lymphoproliverative . gastrointestinal disease . autoimmune
disease . malignancy . B lymphocyte . T lymphocyte . flow
cytometry
Introduction
Primary antibody deficiencies represent the largest group of
primary immunodeficiencies and are characterized by B-cell
dysfunction [1]. Common variable immunodeficiency dis-
orders (CVIDs) is the most heterogeneous group among the
antibody deficiency syndromes and the estimated preva-
lence is 1: 25.000 [2]. The typical clinical presentation of
CVIDs is that of recurrent bacterial respiratory tract infec-
tions but other infections may also occur. Previous gene
defects have found to be associated with the CVIDs pheno-
type (ICOS, TACI, CD19, BAFF-R, MSH5, CD20 and
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CD81) [3–5], however, less than 10% presents within fam-
ilies. In most patients symptoms will start after puberty, and
the diagnosis is often made when the patient has already
reached adulthood. A diagnostic delay is quite common
with a mean of 6–8 years after the onset of symptoms
[6–8], it can however take longer than a decade before a
patient is diagnosed [9]. The diagnostic delay and subse-
quent delay in (immunoglobulin) therapy is thought to be a
major cause of the development of organ damage resulting
in increased morbidity and mortality [8–12]. Pulmonary
damage is the most frequent complication and may result
from recurrent infections and/or immune dysregulation.
Other complications due to the underlying immune dysre-
gulation [7, 9, 13] include lymphoproliferative disease
(granulomatous disease [14], lymphadenopathy and hepa-
tosplenomegaly), autoimmune disease [15], gastrointestinal
disease such as chronic inflammation [16] and an increased
risk of cancer [17, 18]. While a substantial part of the
CVIDs patients remain relatively free of such problems, a
subgroup will develop one or more of these disease related
complications. Attempts have been made to classify the
heterogeneous CVIDs population into more similar sub-
groups by using clinical parameters [9] and flow cytrometric
markers of B- [13, 19, 20] and T cells [21, 22] in order to
define parameters that might predict which patients will be
particularly prone to these complications.
Clinically less severe and much more common antibody
deficiencies are IgG subclass deficiency and Selective anti-
body deficiency with normal immunoglobulins (SADNI)
that are mainly characterized by recurrent sinopulmonary
infections. In 20% of cases however, the finding of lower
IgG subclass levels is merely a laboratory finding that does
not necessarily lead to symptoms [23]. Nevertheless, these
conditions occasionally progress to CVIDs [23, 24]. In the
current retrospective study we determined the spectrum of
clinical manifestations during the long-term follow-up of
adult CVIDs patients in the outpatient clinic of our univer-
sity hospital. For comparison we also included patients with
an IgG subclass deficiency or SADNI. We studied the
clinical features, the immunological characteristics and the
time to diagnosis according to the previous presented clas-
sification systems [9, 13].
Methods
The department of internal medicine and Infectious diseases
at the University Medical Centre Utrecht in The Netherlands
serves as a referral center for adult patients with primary
immunodeficiencies. We performed a retrospective cohort
study of all patients with an antibody deficiency that met the
ESID/Pan-American Group criteria for Immunodeficiency
(PAGID) [25] for Common Variable Immunodeficiency
disorders (CVIDs), IgG- subclass deficiency and Selective
antibody deficiency with normal immunoglobulins (SADNI)
that have attended our outpatient clinic between 1978
and 2011. Selective antibody deficiency with normal
immunoglobulins was defined as a failure to produce
antibodies to polysaccharide vaccines. The response to
23-valent pneumococcal polysaccharide vaccine was
assessed 4 to 6 weeks after vaccination and evaluated
according to age and vaccination history. If the adult
patient was not previously vaccinated with a conjugated
pneumococcal vaccine, the IgG response to the 23 valent
polysaccharide vaccine (Pneu23) was found abnormal when
less than 8 more of the 11 measured antibody titres had
reached a value of ≥1.0 μg/ml.
Patients with a hyper IgM syndrome, XLA or congenital
agammaglobulinaemia were excluded from this study be-
cause of the distinct entity and so where patients with a
secondary hypogammaglobulinaemia due to protein loss,
drugs, malignancy, or infection. All data entries were cross-
checked by an independent physician
Clinical Follow Up Medical records from the patients were
reviewed to obtain patient demographics, clinical manifes-
tations and laboratory data. Clinically stable patients had
usually visited with a frequency of once or twice a year at
our outpatient clinic. Routine physical examination together
with standard laboratory measurements and IgG trough lev-
els were performed in CVIDs patients once or twice a year.
Until recently a pulmonary function test, High Resolution
Computed Tomography (HrCT), abdominal ultrasound and
a gastro- and colonoscopy were performed only in case of
symptoms, this policy has changes the last 2 years.
The time to diagnosis was defined as the time in years
between the year of onset of disease-related symptoms (in-
fectious or non-infectious complications as depicted below)
and the year of diagnosis. Patients that still had ongoing
infections after the start of IgG therapy were scored when
antibiotics were prescribed or when positive bacterial cul-
ture results were obtained in combination with a clinical
diagnosis. To assess the onset of disease we used the fol-
lowing clinical criteria based on the ESID PID warning
signs: 1) ≥4 new middle ear infections within 1 year. 2) ≥2
or more sinus infections within 1 year. 3) ≥2 months on
antibiotics with little effect. 4) Two or more pneumonias
within 1 year or recurrent pneumonias. 5) Recurrent, deep
skin or organ abscesses. 6) Persistent thrush in mouth or
fungal infection on skin. 7) Need for intravenous antibiotics
to clear infections. 8) Two or more deep-seated infections
including septicaemia (i.e. osteomyelitis, meningitis, severe
pneumonia, and arthritis). 9) Gastrointestinal infections with
Giardia Lamblia or Campylobacter.
All immunologic data was entered twice in the database
by different persons.
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Disease Complications Symptomatic chronic pulmonary
disease (CPD) was defined as chronic obstructive pulmo-
nary disease or asthma, bronchiectasis or inflammatory pul-
monary conditions (such as interstitial lung disease). Other
complications related to immune dysregulation have been
previously categorized into five phenotype categories [9]:
(1)lymphoproliferative disease, (2) autoimmune disease, (3)
gastrointestinal disease (4) malignancies or (5) no disease
related complications. Patients were scored according to
these categories (i.e. 1 complication01 category) and indi-
vidual patients were scored for having one or more
complications.
Autoimmunity included cytopenias (chronic autoimmune
hemolytic anemia, chronic autoimmune thrombocytopenia,
and unexplained leucocytopenia) and organ-specific auto-
immunity (rheumatoid arthritis and systemic lupus erythe-
matosus meeting the American Rheumatism Association
[ARA] criteria, Graves’ disease, pernicious anemia and
atrophic gastritis (biopsy proven) and alopecia areata). Lym-
phoproliferative conditions were defined as unexplained
persistent lymphadenopathy (on palpitation, ultrasound or
computer tomography scan), granulomatous disease (biopsy
proven) or hepatosplenomegaly (ultrasound proven).
Gastrointestinal disease was defined as gastrointestinal
symptoms combined with biopsy proven endoscopic abnor-
malities and included Helicobacter pylori positive gastritis,
inflammatory colitis, malabsorption with villous atrophy,
polyps and adenoma. Malignancies were defined as biopsy
proven lymphoid, bone marrow or solid organ cancer.
Laboratory Data Immunoglobulin titres, T and B cell phe-
notyping and in vitro mitogenic and antigenic T cell prolif-
eration responses had been performed in most patients,
between 2007 and 2011. The timing was aimed just before
the administration of immunoglobulins. At the time of these
measurements only one patient used prednisolone 10 mg/
day on a chronic basis. IgG trough levels had been measured
once or twice a year in clinically stable patients during
follow up, and more often in patients with disease-related
complications. In our current daily practice we aim to reach
IgG through levels of at least 8 g/L [26].
CVIDs patients were classified according to the classifi-
cation of EURO Class trial [13], a classification scheme
based on flowcytometric B-cell phenotyping and the
clinical course of the patient. The T and B cell popula-
tions were analyzed by four-color flow cytometry using
whole blood and antibodies to CD3, CD45, CD27,
CD4, CD8, HLA-DR, CD38, CD45RA and CD19,
CD27, CD38, CD10, IgM, IgG, IgA, IgD, respectively,
as described previously [27, 28].
For the T and B lymphocyte functional assays peripheral
blood mononuclear cells (PBMC) were obtained and the
following stimuli were supplemented: phytohemagglutinin,
Concanavalin A, tetanus toxoid, purified protein derivative
(PPD), Candida albicans and diphtheria toxin. Assay con-
ditions were verified by a control sample run in parallel. The
percentage of response was defined by the number of pos-
itive responses to a stimulus divided by the total number of
tests. For B cell differentiation assays, PBMC were cultured
with either pokeweed mitogen or Staphylococcus aureus
antigen and IL-2 [28].
Statistical Analysis Statistical analyses were performed us-
ing Mann–Whitney U tests and Pearson’s chi square tests
with SPSS 15.0 for Windows. A P value of 0.05 or less was
considered significant.
Results
Sixty-one CVIDs patients, nine IgG subclass deficiency
patients and nine patients with Selective antibody deficiency
with normal immunoglobulins (SADNI) were analyzed. All
patients had been diagnosed between 1978 and 2010. The
age at onset of symptoms could be traced in 55 of 61 CVIDs
patients, the year of diagnosis was known for all patients.
Common Variable Immunodeficiency
The baseline characteristics are shown in Table I. The me-
dian age of the 58 CVIDs patients that were still alive at the
time of analysis was 38 years (IQR 26–58 years). Of all
patients that were analyzed 36 were female (59%) and 25
male (41%) and the vast majority of patients were Caucasian
(56 patients, 92%). The recorded follow up in our hospital
since diagnosis ranged between 4 and 13 years (median
7 years). The median age at which CVIDs related symptoms
had started was 17 years (IQR 4–23 years) and the median
age at diagnosis had been 27 years (IQR 14–43 years). The
median time to diagnosis had been 10 years (IQR 5–
16 years), which is addressed in further detail below.
The majority of CVIDs patients (42 patients, 69%) already
had related symptoms before the age of 20 years, however,
only 36% had been diagnosed before the age of 20 suggest-
ing a substantial time to diagnosis (Fig. 1). Notably, two
patients had developed symptoms after the age of 60 years.
In all CVIDs patients intravenous (n045) or subcutane-
ous (n016) IgG substitution therapy had been started. The
vast majority had commenced this therapy within 1 year
after the diagnosis had been established (54 patients, 88%).
All patients had been started on immunoglobulin therapy in
our hospital, either in the department of pediatrics or in the
adult department and follow up of patients took place in our
hospital. Currently, it is standard to start with immunoglobulin
dosing of 0.4 g/kg. The dosage of patients differs and had been
J Clin Immunol (2012) 32:907–921 909
adjusted according to IgG trough levels (aim>8.5 g/l) and
clinical response. Themean IgG trough level in the last decade
was 8.8 g/L. Twenty-six patients (43%) also received antibi-
otic prophylaxis at any point during follow up.
Infections Before immunoglobulin therapy 90% (n055) of
CVIDs patients had suffered from (recurrent) respiratory
infections as shown in Table II. Four patients (7%) had
suffered from severe herpes virus infections (Varicella and/
or Herpes simplex) before diagnosis. Infections of the uro-
genital tract, central nervous system, gastro-intestinal tract
and skin were much less common. Four patients (7%) had
no recurrent or severe infections before the diagnosis and this
remained so thereafter: two patients had arthralgia at the time,
one was screened because of a CVIDs sibling, and the last
patient was screened for chronic non-infectious diarrhea.
The median IgG trough level of the patients with infections
after start of IgG therapy was not significantly different in
comparison to the patients without infections (9.2 g/L vs.
8.7 g/L, respectively). Although eight of the 55 patients
(14%) with respiratory infections became free of infections
after the initiation of IgG therapy the majority of patients still
suffered from respiratory infections (47 of 55 patients, 85%;
Table II), although these appeared to be less frequent. Figure 2
shows the reduction in the number of patients with respiratory
tract infections following the institution of immunoglobulin
therapy. The most prominent reduction was established in
middle ear infections and pneumonia (70–100% reduction;
Fig. 2). However, least effect was accomplished in the occur-
rence of sinusitis: 79% of patients with sinusitis prior to IgG
therapy still suffered from one or more episodes and 60% of
patients with chronic sinusitis were not cured.
Seven (11%) patients had suffered from gastrointestinal
infections before diagnosis of which 4 with Giardia Lamblia,
0
10
20
30
40
50
60
70
80
90
100
0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80
%
 o
f p
at
ie
nt
s
Age,median (yrs)
age at start symptoms 
age at diagnosis
Fig. 1 Age at onset symptoms and at diagnosis of CVIDs in retro-
spective analysis
Table I Baseline characteristics
Pt patients, CVIDs common
variable immunodeficiency dis-
orders, SADNI selective anti-
body deficiency with normal
immunoglobulins. aFirst or sec-
ond degree family members
CVIDs IgG subclass
deficiency
SADNI
(n061) (n09) (n09)
Sex, number of pt (%)
female 36 (59%) 7 (78%) 6 (67%)
male 25 (41%) 2(22%) 3 (33%)
Ethnicity, number of pt (%)
Caucasian 56 (92%) 8 (89%) 9 (100%)
middle East 2 (3%)
Far east 1 (2%) 1 (11%)
mix 2 (3%)
Current age, median (IQR) 38 (26–58) yrs 42 (25–49) yrs 45 (26–53) yrs
Age at start symptoms, median (IQR) 17 (4–23) yrs 16 (4–38) yrs 33 (20–45) yrs
Age at diagnosis, median (IQR) 27 (14–43) yrs 38 (14–45) yrs 44 (21–52) yrs
Time to diagnosis, median (IQR) 10 (5–16) yrs 4 (1–24) yrs 2 (1–10) yrs
Follow up since diagnosis, median (IQR) 7 (4–13) yrs 3 (1–12) yrs 1 (1–3) yrs
Follow up since start therapy, median (IQR) 6,5 (3–13) yrs 3 (1–11) yrs 1 (0–2,5) yrs
Death, number of pt 3 0 0
Causes of death pneumonia, brain
abscess sepsis with
pneumonia
Number of patients with family members
with a confirmed antibody deficiency
6 (in 3 families) 0 0
Number of pt with renal failure 3 0 0
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eight more had a gastrointestinal infection (13%) after start
of therapy. During follow up one patient was diagnosed with
Progressive Multifocal Leukoencephalopathy (PML) during
prednisolone treatment for interstitial pulmonary disease and
one patient with CMV colitis.
Pulmonary Disease and Chronic Sinusitis Symptomatic
chronic pulmonary diseases (CPD) was diagnosed in 20
(33%) CVIDs patients before the start of therapy and this
number increased to 34 (56%) patients after the start of
immunoglobulin therapy (Table III). Before the start of
therapy the majority had been diagnosed with asthma (13
of 20 patients) and none during follow-up. Chest CT
scanning demonstrated the presence of bronchiectasis in
two patients at diagnosis and in another eight during the
follow-up, which is likely to be an underestimation since
only 12 patients underwent chest CT scanning at or
before diagnosis. Of the eight patients diagnosed with
bronchiectasis during follow up only two patients had
mean IgG trough levels <8 g/L. Another three patients
developed interstitial lung disease during follow up. Chronic
sinusitis was present in 20 patients (33%) and responded in
eight patients to IgG therapy.
Other Disease Related Complications Table IV displays the
number and nature of CVIDs related complications and the
different disease complications observed before diagnosis and
during follow up. Despite immunoglobulin therapy patients
still developed complications during follow up.
At diagnosis 18 patients (29%) had one (14 patients) or
more complications (4 patients) and this number increased to
31 patients (51%) during follow up. Of the 18 patients who
already had one or more complication at diagnosis seven
patients developed additional complications of a different
etiology. Additional or new complications developed in 20
patients (33%) during follow-up. Of more than half of the
patients that developed new complications during follow-up
(18 of 31; 58%) these complications could be categorized into
one single category. Lymphoproliferative and autoimmune
complications were the most frequent complications that were
already present at the time of diagnosis. Newly diagnosed
complications during follow up were mostly of a lymphopro-
liferative or gastrointestinal nature. Splenomegaly was fairly
uncommon in our cohort at diagnosis (only three patients at
Table II The number of
patients (%) with infections prior
to diagnosis
Pt patients, CVIDs common
variable immunodeficiency dis-
orders, SADNI selective anti-
body deficiency with normal
immunoglobulins. aGastrointes-
tinal infections: Giardia Lam-
bliae, Campylobacter enteritis,
Salmonella enteritis
CVIDs IgG subclass deficiency SADNI
(n061) (n09) (n09)
Number of
patients (%)
Number of
patients (%)
Number of
patients (%)
None 4 (7%) 0 0
Recurrent respiratory infections 56 (93%) 9 (100%) 9 (100%)
URTI 43 (71%) 3 (33%) 6 (67%)
LRTI 31 (51%) 6 (67%) 5 (56%)
Gastrointestinal infection¹ 7 (12%) 0 0
Recurrent 6/7 (86%) NA NA
Other infections (number of pt)
Abdominal abcess 1 1
Skin infections 3 1
Herpes virus 4
Hepatitis 1
Meningitis 3 2 1
Pancarditis 1
UTR 5 1
Panuveitis (toxoplasma) 1
0
5
10
15
20
25
30
Sinusitis chronic
sinusitis
Otitismedia recurrent
Otitismedia
Pneumonia recurrent
pneumonia
A
bs
ol
ut
e 
nu
m
be
r o
f p
at
ie
nt
s
Respiratory tract infections before and after start of therapy
Before start therapy
After start therapy21%¹
40%¹ 70%¹
87%¹
65%¹
100%¹
Fig. 2 Number of CVIDs patients with respiratory tract infections
before and after start of immunoglobulin therapy. ¹ % decline number
of patients with respiratory tract infections
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diagnosis and another six during follow-up) which is likely an
underestimation since abdominal ultra sound was not per-
formed routinely. None of the patients had been diagnosed
with cancer before the diagnosis of CVIDs and during follow-
up four patients developed a malignancy (anal carcinoma at
the age of 27, thyroid cancer at the age of 22, seminoma at the
age of 58 and bladder cancer at the age of 61). Three of these
patients also had other complications as a result of extended
immune dysregulation (Table IV). All three patients who
developed end stage organ failure during follow up were
diagnosed with terminal renal insufficiency and are currently
on hemodialysis. In two patients renal insufficiency was
caused by underlying vascular problems and one patient was
diagnosed with interstitial nephritis.
The IgG trough levels of the patients that had developed
new complications since IgG substitution did not differ
significantly of that of patients that had not.
Time to Diagnosis The median time to diagnosis of CVIDs
was substantial, 10 years (IQR 5–16 years) compared to
2.5 years (IQR 1–18 years), p00.016 of the partial antibody
deficiencies (IgG subclass deficiency and SADNI taken
together).Two patients with bronchiectasis at diagnosis had
a diagnostic delay as long as 24 and 32 years, respectively.
Figure 3 shows the age at the onset of symptoms and the age
at the time of CVIDs diagnosis as well as the time to
diagnosis in relation to the number of complications.
Patients with one or two complications had been significant
older at the time the CVIDs diagnosis was made compared
to the patients without complications. (n017 vs. 44, 39 year
vs. 28 year, p00.03) The median time to diagnosis in the
group of patients with non-infectious complications was
seven years longer in comparison to the group of patients
without these disease complications (10.2 vs. 17.6 years,
p00.026). Patients with autoimmune disease (10 patients)
had a median diagnostic delay of 17 years (IQR 0–
39 years). Especially alopecia had been present long
before the diagnosis of CVIDs was made (mean 25 years,
range 11–39 years). All four patients with granulomatous
disease had a relative long time to diagnosis (respectively
32, 21, 16 and 7 years). Of the four patients (6.5%) with
gastrointestinal disease diagnosed before the diagnosis of
CVIDs, the diagnostic delay was 32, 10, 7 and 5 years
respectively. The diagnostic delay of the three patients
that had died during follow up had been 28, 14 and
12 years, respectively.
Deaths Four patients had died during follow-up. One male
patient had been diagnosed with CVIDs 14 years after his
symptoms started at the age of 63 years. He also suffered
from cardiovascular disease and diabetes mellitus and died
at the age of 70 years as the result of pneumonia. A female
patient died at the age of 31 years due to a brain abscess. She
had been diagnosed with CVIDs at the age of 27 after
suffering from upper respiratory tract infections, Herpes
Zoster infections and lymphoproliferative disease for 12 years
(since the age of 15). The third patient, also a female, died at
the age of 49 due to a sepsis of unknown cause. She had been
diagnosed at the age of 45 years but had suffered from nu-
merous clinical problems years before that (since the age of
17 years).
Laboratory Evaluation The median IgG of all CVIDs
patients at diagnosis was 3.8 g/L (IQR 2.1–4.9 g/L)
(Table V).
Patients who were diagnosed with lymphoproliferative
conditions, autoimmune disease and gastrointestinal disease
had a lower IgG at diagnosis compared to those without
complications. (2.0 g/L (IQR 1.2–3.6) p00.02; 2.8 g/L (IQR
1.6–4.4) p00.03; 1.5 g/L (IQR 0.63–2.9) p00.002 vs. 4.5 g/L
(IQR 2.8–5.2) respectively).
B Cell Phenotype During routine clinical evaluation flow-
cytometric B-cell phenotyping had been performed in 46
patients, and 70% of these patients had normal numbers of
total CD19 positive B cells. Patients with complications
related to immune dysregulation had lower absolute numb-
ers of CD19 positive B lymphocytes then those that did not
(median 256/mm³ (IQR 189–384/mm³) vs. 111/mm³ (IQR
39–308/mm³), p00.007). Furthermore, we established sig-
nificant differences in the absolute numbers of cells in the B
cell subsets between patients with and without complica-
tions. (Table VI) According to the EURO class classifica-
tion, two patients (4%) had less than 1% of CD19+ B cells
Table III Symptomatic chronic
lung disease in 61 CVIDs
patients
aSymptomatic chronic lung dis-
ease was defined as chronic ob-
structive pulmonary disease or
asthma, complications due to
infections (e.g. bronchiectasis)
and auto inflammatory pulmo-
nary conditions such as intersti-
tial lung disease
Before start of therapy After start of therapy
Total number of patients (%) Total number of patients (%)
Symptomatic chronic pulmonary diseasea 20/61 (33%) 34/61 (56%)
Structural airway changes (bronchiectasis) 2/20 (10%) 10/34 (29%)
Interstitial lung disease 6/20 (30%) 9/34 (26%)
Granulomatous disease 3/6 (50%) 3/9 (33%)
Fibrosis 3/6 (50%) 6/9 (67%)
COPD/asthma 13/20 (65%) 16/34 (47%)
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Table IV CVIDs related com-
plications before and after start
of immunoglobulin therapy in
61 CVIDs patients
apatients can have more than 1
condition
bOf the three patients with cyto-
penia, one male suffered from
autoimmune hemolytic anemia
and two females from Idiopathic
thrombocytopenic purpura
cBefore diagnosis of CVID: one
patient was diagnosed with
diabetes Mellitus and another
patient with Systemic lupus
erythematodes., After diagnosis
one patient was diagnosed with
hypothyroidism
Before start of therapy After start of therapy
Number of patients (%) Number of patients (%)
Complications
Yes 18 (30%) 31 (51%)
No 43 (70%) 30 (49%)
Number of complications/patient
0 43 (70%) 30 (49%)
1 14 (23%) 18 (29,5%)
2 4 (6,5%) 9 (15%)
3 0 4 (6,5%)
4 0 0
Type of disease (Number of patients) ¹
Lymphoproliverative 8/61 (13%) 17/61 (28%)
Granulomatous disease 4 8
Lymphadenopathy 4 11
Hepatosplenomegaly 4 11
Spleen 2 8
Liver 1 1
Both spleen and liver 1 2
Autoimmune disease 10/61 (16%) 14/61 (23%)
Non-septic arthritis 2 2
Autoimmune cytopenia 3b 9
Organ related 2c 3c
Alopecia 3 3
Malignancy 0 4/61 (7%)
Anal 0 1
Thyroid 0 1
Seminoma 0 1
Bladder 0 1
Gastrointestinal disease 4/61 (6,5%) 13/61 (21%)
Oesofagits 2
Gastritis 1 7
Villous atrophy 1 5
Inflammation ileum/colon/rectum 2 8
Angiodysplasy 1
Polyps/adenoma 1 4
Malignancy 1
Nodular lymphoid hyperplasia 6
Number of patients with phenotypes
None 43 (70%) 30 (49%)
Lymphoproliverative 4 (7%) 5 (8%)
Autoimmune 9 (15%) 8 (13%)
gastrointestinal disease 1 (1.5%) 4 (6,5%)
Malignancy 0 1 (1,5%)
Lymphoproliverative and autoimmunity 1 (1.5%) 3 (5%)
Lymphoproliverative and gastrointestinal disease 3 (5%) 5 (8%)
Lymphoproliverative and malignancy 0 1 (1,5%)
Autoimmune, malignancy and gastrointestinal disease 0 1 (1,5%)
Lymphoproliverative, autoimmune and gastrointestinal disease 0 2 (3%)
Lymphoproliverative, malignancy and gastrointestinal disease 0 1 (1,5%)
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of lymphocytes of which one patient had been diagnosed
with an autoimmune complication and the other patient with
a lymphoproliferative condition and gastrointestinal disease.
Patients with ≥1% B cells of total lymphocytes were further
divided into two categories based on the percentage of class-
switched memory B cells deficiency (<2% or ≥2% of the
circulating B cell pool). The percentage of patients with
<2% of class switched memory B cells was 18% (11 of 46
patients). Seven of these 11 patients (63%) had one or more
non-infectious complications. Patients with complications
and >2% of class switched memory B cells had lower
median numbers of class switched memory B cells then
patients without complications. (11.2/mm³ (IQR 6.6–23.2/
mm³) vs. 3.6/mm³ (IQR 0.5–10.7/mm³), p00.013).
Table VI shows the median numbers within the B cell
compartment and each different complication. Low numbers
of switched memory B cells was associated with autoimmune
and lymphoproliferative disease. Furthermore patients with
splenomegaly and granulomatous disease had lower median
numbers of switched memory B cells vs. patients without
these conditions. (this is not shown in table 6: 9.8/mm³ (IQR
4.6–23/mm³) vs. 0.4/mm³ (IQR 0.1–3.5/mm³), p00.001,
1.5/mm³ (IQR 0−10/mm³) vs. 11.5/mm³ (IQR 7–23/mm³)
p=0.016 respectively). Figure 4 shows the relation between
the number of complications and the B cell subsets. Although
not significant, there seems to be a trend of a decrease in the
absolute numbers of naive B cells, as the number of compli-
cations increases. Patients with one or more complication
had significant lower naïve B cells (158 vs. 71.5 cells/μl
p=0.04) and IgG memory B cells (7 vs. 1.5 cell/ μl
p=0.01).
T Cell Phenotype T lymphocyte abnormalities were present
in almost 20% of CVIDs patients (Tables V) and the majority
of patients with decreased numbers of CD3, CD4 and CD8
positive T cells had been diagnosed with one or more compli-
cation, most often lymphoproliferative and autoimmune
diseases. Table VII shows the median absolute numbers with-
in the T cell compartment in patients with and without com-
plications. Patients with one or more complications had
significant lower numbers of CD3 and CD4 positive T cells.
Furthermore patients with autoimmune disease had significant
lower absolute numbers of CD3, CD4 and CD8 positive T
cells compared to patients without complications. Absolute
numbers of naive CD4+ T cells and naive CD8+ T cells were
significant lower in the group of patients with any complica-
tion (Table VII).
Figure 5 shows the relation between the number of com-
plications and T lymphocytes subsets. The number of abso-
lute CD3+and CD4+ T lymphocytes was significantly lower
in the group of patients with one or more complication. All
50 patients that were tested on lymphocyte proliferation had
normal responses on mitogens PHA, ConA and PWM (48
patients were tested) and only a few patients responded
abnormal on Candida (41/45 patients, 2%), PPD (5/43
patients, (12%), tetanus toxoid (3/44 patients, 7%) and
diphtheria toxin (6/40 patients, 15%).
Partial Antibody Deficiency
Of the nine patients with IgG subclass deficiency most were
Caucasian (8 patients, 89%) and one patient originated from
the Far East. Seven patients were female (78%) and two
male (22%). The median age when symptoms started was 16
years (IQR 4-37 yrs) and the median age at diagnosis was 38
years (IQR 14-45 yrs). None of the patients died during
follow up. Four patients were diagnosed with an IgG4
deficiency of which one had IgG therapy and one antibiotic
prophylaxis. Two patients had an IgG2 deficiency, one on
IgG therapy and antibiotics prophylaxis as well and one
patient was on antibiotics only. Two patients had a IgG3
deficiency, both on antibiotic prophylaxis and one patient
with a combined IgG2,3 and 4 deficiency who was treated
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by IgG therapy and antibiotics prophylaxis. The two patients
without therapy became free of infections. One out of four
patients on antibiotic prophylaxes and one on out of
three patients on IgG therapy became infection free.
As shown in Table II all patients had infections prior to
diagnosis which mainly consisted of respiratory tract infec-
tions. Two of the 9 patients with an IgG subclass deficiency
had suffered form from bacterial meningitis. In contrast to
CVID, patients with a selective IgG deficiency did not suffer
from gastrointestinal infections.
Despite a median time to diagnosis of ten years (IQR 0–
33 yrs). None of the patients developed chronic pulmonary
disease or other complications during follow up.
Of the nine patients diagnosed with Selective antibody
deficiency with normal immunoglobulins (SADNI) six were
female (67%) and three male (33%) and all were Caucasian.
The median age at start of the symptoms was 33 years (IQR
20–44 yrs) and the median age at diagnosis was 44 years
(IQR 21–50 yrs). The median IgG at diagnosis was 10.3 g/L
(IQR 6.6–17.7 g/L). None of the patients died during follow up.
Two patients were treated by immunoglobulin substitu-
tion and four patients by prophylactic antibiotics. All
patients had infections (mainly respiratory tract) prior to
diagnosis. Four patients without therapy, one of four
patients on prophylactic antibiotics and one out of two
patients on IgG therapy became free of infections. Two
patients had chronic pulmonary disease at the time of diag-
nosis which is uncommon in SADNI patients of which one
patient was diagnosed with SADNI because of the presence
of bronchiectasis. This patient was started on immunoglob-
ulin therapy and experienced fewer infections thereafter.
The other patient was diagnosed with fibrosis on High
resolution CT scanning of the lungs diagnosed after an epi-
sode with a complicated pneumonia. The median diagnostic
delay was 6.5 years (IQR 1–30 yrs). Of the two patients with
chronic pulmonary disease, only the patient with bronchiec-
tasis had a considerable diagnostic delay (33 year).
Table VIII shows the decline in infections before and after
diagnosis in the group of patients with an IgG subclass defi-
ciency (n09) or selective antibody disorder (SADNI, n09).
Table V Immunological parameters of CVIDs patients
(n061) Females (n036) Males (n025)
Ig levels at diagnosis (g/L) Median (range) Median (range) Median (range)
IgG (7,0–16,0) 4,0 (2,3–5,1) 4,0 (2,4–5,0) 3,9 (1,12–5,3)
IgA (0,7–4,0) 0,1 (0,0–0,6) 0,3 (0,0–0,66) 0,04 (0,2–0,42)
IgM (0,4–2,3) 0,4 (0,22–0,9) 0,5 (0,26–1,04) 0,31 (0,2–0,43)
Number of patients (%) with
lymphocyte below lower limit countsa
Number of patients (%) Median (range) Number of patients
with complications
CD3b 10/52 (19,2%) (376–684 cells/ul) 9/10
CD4b 12/54 (22,2%) (55–344 cells/ul) 9/12
CD8b 5/52 (9.6%) (37–155 cells/ul) 5/5
Inverted CD4/CD8 ratiob
Under lower limit 10/53 (18.7%) (0.30–0.90) 5/10
Above upper limit 7/53 (13.2%) (3.5–9.0) 4/7
a absolute lymphocyte counts per cubic millimeter
b reference values: CD3 (100–400), CD4 (400–1300), CD8 (200–700), CD4/CD8 ratio (1,1–3,2)
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Immunophenotyping was performed in seven of the nine IgG
subclass patients and in three of the nine SADNI patients. The
median absolute numbers of B cells were normal in both
groups (subclass deficiency 360/mm3 (IQR 170–583/mm3),
SADNI 201/mm3 (IQR 165–484/mm3). Within the B cell
compartment of IgG subclass patients the absolute median
numbers of IgM memory B cells were elevated (IgM memory
B cells: 54.5/mm3, IQR 20–111/mm3, ref values: 20 (10–39/
mm3). The B cell compartment of SADNI patients showed a
decreased absolute median numbers of naïve B cells and an
elevated number of IgM memory B cells (naïve B cells: 61/
mm3 IQR 54–315/mm3, ref values: 153/mm3 (72–257/mm3)
and IgMmemory B cells: 46/mm3 IQR 43–56/mm3, ref val-
ues: 20 (10–39/mm3)
Discussion
CVIDs is the most common and most diverse primary
antibody deficiency. It consists of a heterogeneous group
of patients with variable infectious and immunological man-
ifestations. CVID s patients share clinical features but differ
in their clinical course probably due to different underlying
immunopathogenic mechanisms which are largely unknown
as is the genetic cause.
This study presents the clinical and immunological data
on a cohort of 61 patients. We found that the initial clinical
presentation in our cohort was comparable to other cohort
studies that have been published in the past [7, 29, 30]. It
has been reported that 90% of CVIDs patients suffer from
one or more episodes of lower respiratory tract infections
prior to diagnosis [31] and our findings were compatible to
that. Because of the retrospective nature of the study the
exact number of infections per year could not be traced and
we were only able to distinguish patients that still suffered
from infections from those that did not. When these two
groups were compared, median trough levels did not differ
significantly. This might be due to the fact that in our clinic
we aim for a IgG trough level above 8 g/L for every patient
and to the fact that this cohort is too small to find differences
in IgG trough levels. The overall percentage of patients
affected by new respiratory infections decreased during
follow-up in our cohort. However, the effect on chronic
sinusitis and acute episodes of sinusitis was less impressive.
Previous reports have shown that immunoglobulin therapy
is effective in preventing acute respiratory infections [26,
Table VI Median absolute numbers of B lymphocyte subset in CVIDs patients with and without complications
Total B cells B cell naive RBEb IgM memory
CD19+N 100–400 CD19+sIgM+sIgD+
CD10-CD27-N 72-257c
CD19+sIgD+CD10+CD38+
N 6-41c
CD19+sIgM+sIgD+
CD27+N 10-39c
No complicationsa (n024) 256 (189–384) 158 (105–257) 19,5 (5–37) 30 (14–62)
Complicationsa
Totala (n028) 111 (39–308)* 71,5 (37–201)* 11,5 (5–23) 12 (2–61)
Lymphoproliverativea (n016) 110,5 (16–308)* 65,5 (31–208)* 10,5 (2–18) 15,5 (2–71)
Auto immunea (n013) 79 (29−139)** 60 (39−114)* 11,5 (4−21) 8,5 (2−28)*
Gastrointestinal
diseasea (n013)
79 (22–322)* 79 (35–212) 11 (2–27) 22 (1–64)
IgG memory IgA memory Class switched memory B cells
CD19+sIgG+CD27+
N 2-51c
CD19+sIgA+CD27+
N 1-20c
CD19+IgD-CD27+
N 2-40c
No complicationsa (n024) 7 (4–13) 3,5 (2–9) 11,5 (7–23)
Complicationsa
Totala (n028) 1,5 (0–6)** 2 (0–6) 3,5 (0,2–11)*
Lymphoproliverativea (n016) 1 (0−7)* 2 (0−10) 3,5 (0−12)*
Auto immunea (n013) 1 (0–2)* 1,5 (0–3)* 3 (0–5)*
Gastrointestinal diseasea (n013) 1 (0–11)* 3 (0–9) 4 (1–26)
Complications: Lymphoproliverative-, Auto immun- and gastrointestinal disease. Malignancies excluded
aMedian absolute numbers/mm³ (IQR)
b Recent bone marrow immigrants
c From: van Gent et al., Clinical Immunology (2009) 133, 95–107
*<0,05 and **<0,001
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32–36]. Structural airway changes (e.g. bronchiectasis and
bronchial wall thickening), parenchymal and interstitial
lesions and chronic sinusitis are common in adult CVIDs
patients (38–79%) [6, 11, 31, 37–41] Despite the consider-
able time to diagnosis in our cohort the prevalence of
symptomatic chronic pulmonary disease and chronic sinus-
itis at diagnosis was lower in compared to other reports (18–
40% [11, 29, 31, 42, 43] and 36–90% respectively [29, 44].
In our group only 10% of the patients with chronic pulmo-
nary disease (CPD) were found to have bronchiectasis prior
to diagnosis of CVIDs, this increased to 29% with a median
follow up of 7 years [4–13]. However, this is likely an
underestimation as high resolution computed tomography
(hRCT) has not been applied for every patient at diagnosis
and during follow up. Progression to CPD continued in our
cohort, despite IgG replacement therapy with adequate IgG
trough levels (>8 g/L) [26] which seems to be in accordance
with previous reports [29, 42, 45–47] The pathogenesis of
CPD include recurrent respiratory tract infections but also
non-infectious inflammatory conditions caused by immune
dysregulation such as granulomatous and interstitial pulmo-
nary disease [41] Immunoglobulin therapy has proven to be
effective in preventing acute respiratory infections but
conflicting data exist on the beneficiary effect on chronic
pulmonary damage [11, 29, 42, 45–47] Therefore the con-
tribution of immune dysregulation to CPD cannot be under-
estimated stressing the importance of early detection and
directed therapy for chronic lung disease.
Chapel et al. [9] defined 5 distinct clinical phenotypes:
patients with no complications, with autoimmunity, with poly-
clonal lymphocytic infiltration, with gastrointestinal disease
or with malignancy. In our patient cohort 29% of patients had
one or more complications at diagnosis, which increased to
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Table VII Median absolute numbers of T lymphocyte subset in CVIDs patients with and without complications
CD3 CD4 CD8 Activated CD4 T cell Naive CD4 T cell
(N 700–1900) (N 400–1300) (N 200–700) (N 2,5–8,5) (N 240–790)
No complicationa (n024) 1450 (1050–1899) 812 (607–1131) 533 (372–738) 8 (3–17) 367 (223–580)
Complicationsa
totala (n028) 968 (671–1649)* 572 (330–989)* 379 (222–619) 12 (6–24) 121 (52–390)*
Lymphoproliferativea
(n016)
792 (643–1589)* 566 (357–1021) 270 (151–597)* 18–(9–27) 115 (14–406)*
Auto immunea (n013) 806 (1050–1899)* 512 (261–578)* 335 (224–562)* 11 (5–29) 84 (43–221)*
Gastrointestinal diseasea
(n013)
975 (560–1604)* 601 (419–989) 311 (153–558)* 11 (2–24) 99 (21–269)*
Eff/Mem CD4 T cell Activated CD8 T cell Naive CD8 T cell Eff/Mem CD8 T cell
(N 150–500) (N 4–19) (N 220–400) (N 50–190)
No complicationa 418 (306–548) 9 (3,0–16) 308 (214–357) 233 (147–363)
Complicationsa
totala (n028) 412 (250−569) 14 (5−25) 99 (43−156)** 237 (120−429)**
Lymphoproliferativea
(n016)
507 (164–584) 20 (7–41)* 86 (30–158)** 141 (106–392)*
Auto immunea (n013) 336 (244–435) 11 (6–18) 84 (40–135)* 217 (120–495)*
Gastrointestinal diseasea
(n013)
513 (156–613) 7 (3–23) 64 (29–125)** 181 (106–345)*
Complications: Lymphoproliverative-, Auto immun- and gastrointestinal disease. Malignancies excluded
aMedian absolute numbers/mm³ (IQR)
*<0.05 and **<0.001
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51% of patients during follow up and despite immunoglobulin
therapy. Compatible to other cohort studies [7, 29] the most
common complications were autoimmune and lymphoproli-
ferative disease. Chapel et al. described a similar frequency of
33% and 22% respectively [9]. The increase was applicable
for all categories of complications, however it was most
prominent in gastrointestinal disease (6.5% to 21%), de-
scribed earlier [29]. Nevertheless, we established a lower
prevalence of symptomatic gastrointestinal disease compared
with other reports [7, 29]. Furthermore only 10% had chronic
diarrhea compared 20–60% chronic diarrhea in other reports
from the literature) [7, 16, 48, 49] The progression of chronic
gastrointestinal diseases may still occur in patients with a
primary antibody deficiency since IgG substitution will only
substitute IgG, while IgA and IgM, the major secretory anti-
bodies at mucosal surfaces are not replaced, and secondly,
immune dysregulation and T cell abnormalities may contrib-
ute to gastrointestinal disease. Cytopenia was the most fre-
quently diagnosed autoimmune disease. Three patients
developed alopecia areata before diagnosis of CVIDs while
alopecia in CVIDs has been described only in case reports
[50–52].Malignancies are more common in CVIDs patients at
a younger age, especially gastrointestinal cancer and lympho-
ma [17, 18, 29] In our cohort four patients were diagnosed
with cancer of which two at a really young age (thyroid cancer
(22 years) and anal carcinoma (27 years)). Pulmonary and
other complications continue despite adequate replacement
pointing at other causes responsible for this complica-
tion. Failure to diagnose CVIDs and therefore delaying
the start of adequate therapy for specific conditions can
cause considerable morbidity, particularly in case of
progressive airway disease. The median time to diagno-
sis for the CVIDs patients in our cohort (10 years) was
comparable to previously reported (3–15 years) [7, 9,
10, 29, 43, 53]. In a registry of nearly 400 patients
from the United Kingdom, Germany, Sweden and the
Czech republic, 20% of patients were diagnosed more
than 15 years after onset of symptoms [9]. In our study
the mean time to diagnosis in the group of patients with
one complication or more was 7 years longer (p<0.05) in
comparison to the group of patients without complications.
Although IgG substitution therapy seemed to have little effect
on the development of these or new complications, reducing
the diagnostic delay is essential in order to reduce infection-
related complications such as pulmonary damage and chronic
sinusitis.
It must be stressed that the age at which symptoms had
started is not a reliable parameter in that it is a retrospective
estimation and cannot be calculated in months and variation
might even be 1 or 2 years.
Different classification schemes using clinical parameters
[9], flow cytometric markers of B- [13, 19, 20] and T cells
[21] have been proposed in order to subdivide the hetero-
geneous CVIDs population into more homogenous groups
which might yield clues for possible pathogenic mecha-
nisms as well lead to a model to predict which patients are
prone to complications. Recently the first genome-wide
association and gene copy number variation (CNV) study
in patients with CVIDs was performed which uncovered
multiple novel susceptibility loci for CVIDs confirming
the polygenic nature. Nevertheless these results could provide
new mechanistic insights into immunopathogenesis [54].
The EURO class [13] trial established an association
between a reduction in class switched memory B cells
(<2%) and CVIDs related complications was associated
with a higher risk for splenomegaly and granulomatous
disease. In other studies this association between a reduction
of peripheral switched memory B cells and other clinical
complications was confirmed [13, 19, 20, 55]. In our study,
most patients had been diagnosed long before the
Table VIII Number (%) of patients with infections before and after diagnosis in the group of patients with an IgG subclass deficiency (n09) or
selective antibody disorder (SADNI, n09)a
Before diagnosis After diagnosis
Number of patients (%) Number of patients (%)
IgG Subclass deficiency SADNI IgG Subclass deficiencyc SADNId
Sinusitis 1 (11%) 3 (33%) 2 (22%) 2 (22%)
Otitis Media 1 (11%) 1 (11%) 1 (11%) 1 (11%)
Pneumonia 5 (56%) 3 (33%) 1 (11%) 0
Otherb 4 (44%) 2 (22%) 2 (22%) 0
a Patients can have more than 1 condition
b Subclass deficiency: hidradenitis, meningitis, UWI. SADNI: mastitis, abdominal abcess, meningitis
c Two patients without therapy, four patients on antibiotic prophylaxis, one patient on IgG therapy, two patients on IgG therapy and antibiotic
d Four patients without therapy, three patients on antibiotic prophylaxis, one patient on IgG therapy and one patient on IgG therapy and Ab
profylaxe
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bloodsampling. However, it is generally believed that the
values in T and B cell phenotyping are more or less stable
during the lifecycle of the patient. To our knowledge no data
is published on this subject, it has only been confirmed by
word of mouth during scientific sessions. The overall inci-
dence of patients with a low percentage (<2%) of class
switched memory B cells was low. However, the association
between autoimmune disease and a low percentage (<2%)
of class switched memory B cells was established as well as
with splenomegaly and granulomatous disease. Furthermore
patients with complications and >2% of class switched
memory B cells had lower median numbers of class
switched memory B cells then patients without complica-
tions. Therefore, patients with complications were more
affected in their number of class switched memory B cells
than patients without any complicating disease. Also,
patients with complications related to immune dysregulation
had lower absolute numbers of CD19 positive B lympho-
cytes then those that did not described by Yong et al. [56].
Subsequently, we found a correlation between CD3+ T cells,
CD4+ T cells, naive CD4+ and CD8+ T cells and specific
complications as previous described in the literature [22].
Few studies have investigated the correlation with clinical
features [22, 57]. One study found that a low count of
absolute naive CD4+ T cells was associated with spleno-
megaly and autoimmunity. It is likely that T cells play an
important role in the pathogenesis of auto inflammatory
conditions in CVIDs [58–60]. According to some studies
the T-cell dysregulation such as the decrease in naive CD4+
T cells in certain patients could be due to abnormal thymus
function [22, 60], however accelerate T cell turnover as a
result of the high infectious burden may also be an expla-
nation [22].
In comparison, IgG subclass deficiency and SADNI
patients did not develop any complications during follow-
up as described in the sparse previous studies [61–63]. The
effect of therapy (IgG therapy or antibiotic prophylaxis) in
these patients was most prominent on the occurrences of
pneumonia. Although a decline in the number of patients
with infections occurred in the group of partial antibody
deficiencies, no distinction could be made between patients
on or off therapy. Data about the immunological and clinical
profile of immunoglobulin subclass deficiency are sparse in
the literature. It appears that patients with IgG1 and/or IgG3
deficiency are more likely to have chronic and recurrent
infections of the lower airways, while those with IgG2
and/or IgG4 deficiency are more likely to suffer from sinus-
itis and otitis [64]. Interestingly, in our cohort two of 9
patients had suffered from bacterial meningitis, which to our
knowledge has not been described in earlier publications.
In conclusion, in our study the spectrum of illness for
patients with CVIDs is in concordance with previous reports
with predominantly respiratory tract infections prior to
diagnosis. Also, infections diminished considerably as a
result of IgG therapy, although this effect was considerably
less for acute and chronic sinusitis. Second, the develop-
ment of chronic pulmonary disease non-infection related
complications was not halted by adequate immunoglobulin
therapy. A considerable number of CVIDs patients already
had complications at the time of diagnosis and this number
of patients increased despite immunoglobulin therapy. In
our cohort an association between immunological parame-
ters and the specific complications related to CVIDs could
be established within the B and T cell compartment.
The time to diagnosis in the group of patients with
complications was significantly longer comparable to the
group of patients without complications, and especially
patients presenting with autoimmune phenomena are often
under diagnosed. It remains important to increase awareness
among doctors for the variable clinical presentations and
manifestations of CVIDs. Specific disease related therapy
would be started in an earlier stage of the disease which
could affect morbidity and mortality.
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